ATTRACTIVE APPROACHES in DRUG DELIVERY: BIO-BASED CARRIERS for siRNA TARGETING
Öz
Functional characterization of genes can be determined by disruption of gene expression. This provides powerful approach in designing novel treatment strategies. RNA interference (RNAi) is a natural phenomenon that can aid in the study of post-transcriptional regulation of genes. This mechanism can be stimulated via introduction of double stranded RNA (dsRNA) in a cell. Synthetic short/small interfering RNAs (siRNA) can be utilized to trigger down-regulation of desired genes via transfecting into mammalian cells. Recently, utilization of bio-based polymers has been an attractive approach in drug delivery for medical applications. This review article describes the advantages of exploiting bio-based polymeric carriers for siRNA targeting, as bio-therapeutics. Here, we report the current developments, safety and delivery of bio-based siRNAs via polymeric carriers. Additionally, cancer genetics and metabolic disorders including obesity and diabetes pertaining to the progress in clinical applications have been highlighted.
Anahtar Kelimeler
Kaynakça
- [1]. Wang X, Wang YQ, Chen Z, Shin DM: Advances of Cancer Therapy by Nanotechnology. Cancer Research and Treatment; 2009, 41:1-11. [2]. Chapman EJ, Carrington JC: Specialization and evolution of endogenous small RNA pathways. Nature Reviews Genetics; 2007, 8:884-896. [3]. Lee SJ, Son S, Yhee JY, Choi K, Kwon IC, Kim SH, Kim K: Structural modification of siRNA for efficient gene silencing. Biotechnol Adv.: 2013, 31:491-503. [4]. Lee SJ, Kim MJ, Kwon IC, Roberts TM: Delivery strategies and potential targets for siRNA in major cancer types. Adv. Drug Deliver. Rev.; 2016, 104:2-15. [5]. Tuzmen S, Tuzmen P, Arora S, Mousses S, Azorsa D: RNAi-based functional pharmacogenomics. Methods Mol. Biol.; 2011, 700:271-290. [6]. Kang S, Hong YS: RNA interference in infectious tropical diseases. Korean Journal of Parasitology; 2008, 46:1-15. [7]. Ding SW, Voinnet O: Antiviral immunity directed by small RNAs. Cell; 2007, 130:413-426. [8]. Obbard DJ, Gordon KHJ, Buck AH, Jiggins FM: The evolution of RNAi as a defence against viruses and transposable elements. Philosophical Transactions of the Royal Society B-Biological Sciences 2009, 364:99-115. [9]. Saurabh S, Vidyarthi AS, Prasad D: RNA interference: concept to reality in crop improvement. Planta; 2014, 239:543-564. [10]. Tijsterman M, Plasterk RHA: Dicers at RISC: The mechanism of RNAi. Cell; 2004, 117:1-3. [11]. Elbashir SM, Lendeckel W, Tuschl T: RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes & Development; 2001, 15:188-200. [12]. Xu CF, Wang J: Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences; 2015, 10:1-12. [13]. Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S: Functional evidence implicating S100P in prostate cancer progression. Int. J. Cancer; 2008, 123:330-339. [14]. Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, Henderson MC, Choi YH, Briollais L, Ozcelik H, Tuzmen S: NCI60 Cancer Cell Line Panel Data and RNAi Analysis Help Identify EAF2 as a Modulator of Simvastatin and Lovastatin Response in HCT-116 Cells. Plos One; 2011, 6. [15]. Sarett SM, Nelson CE, Duvall CL: Technologies for controlled, local delivery of siRNA. J. Control Release; 2015, 218:94-113. [16]. Conde J, Ambrosone A, Hernandez Y, Tian FR, McCully M, Berry CC, Baptista PV, Tortiglione C, de la Fuente JM: 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics. Nano Today; 2015, 10:421-450. [17]. Robb GB, Rana TM: RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol. Cell; 2007, 26:523-537. [18]. Meng H, Mai WX, Zhang HY, Xue M, Xia T, Lin SJ, Wang X, Zhao Y, Ji ZX, Zink JI, Nel AE: Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo. Acs Nano; 2013, 7:994-1005. [19]. Resnier P, Montier T, Mathieu V, Benoit JP, Passirani C: A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials; 2013, 34:6429-6443. [20]. Mittal V: Improving the efficiency of RNA interference in mammals. Nature Reviews Genetics; 2004, 5:355-365. [21]. Seyhan AA: RNAi: a potential new class of therapeutic for human genetic disease. Hum. Genet.; 2011, 130:583-605. [22]. Bumcrot D, Manoharan M, Koteliansky V, Sah DWY: RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chemical Biology; 2006, 2:711-719. [23]. Seyhan AA, Alizadeh BN, Lundstrom K, Johnston BH: RNA interference-mediated inhibition of semliki forest virus replication in mammalian cells. Oligonucleotides; 2007, 17:473-484. [24]. Son Aydin TS, Hizel C: Designing and Implementing Pharmacogenomics Study: Appropriateness and Validation of Pharmacogenomics. In Omics for Personalized Medicine,. Springer; 2013: 97-122 [25]. Tüzmen S, Azorsa D.,Weaver D., Caplen N., Kallioniemi O., Mousses S: Validation of siRNA knockdowns by real-time quantitative PCR. International qPCR Symposium and Application Workshop; 2004. [26]. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG: Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol.; 2003, 5:834-839. [27]. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, et al: Position-specific chemical modification of siRNAs reduces "off-target'' transcript silencing. Rna-a Publication of the Rna Society; 2006, 12:1197-1205. [28]. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, Leake D, Marshall WS, Khvorova A: Off-target effects by siRNA can induce toxic phenotype. Rna-a Publication of the Rna Society; 2006, 12:1188-1196. [29]. Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K: siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res.; 2004, 32:W124-W129. [30]. Gandhi NS, Tekade RK, Chougule MB: Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J. Control Release; 2014, 194:238-256. [31]. Reischl D, Zimmer A: Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine-Nanotechnology Biology and Medicine; 2009, 5:8-20. [32]. Kanasty R, Dorkin JR, Vegas A, Anderson D: Delivery materials for siRNA therapeutics. Nature Materials; 2013, 12:967-977. [33]. Whitehead KA, Langer R, Anderson DG: Knocking down barriers: advances in siRNA delivery. Nature Reviews Drug Discovery; 2009, 8:129-138. [34]. Conde J, Arnold CE, Tian FR, Artzi N: RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment? Materials Today; 2016, 19:29-43. [35]. Dominska M, Dykxhoorn DM: Breaking down the barriers: siRNA delivery and endosome escape. J. CELL SCI.; 2010, 123:1183-1189. [36]. Marques JT, Williams BRG: Activation of the mammalian immune system by siRNAs. Nature Biotechnol.; 2005, 23:1399-1405. [37]. Gomes-da-Silva LC, Simoes S, Moreira JN: Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cell. Mol. Life Sci.; 2014, 71:1417-1438. [38]. Castanotto D, Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature; 2009, 457:426-433. [39]. Philipp A, Zhao XB, Tarcha P, Wagner E, Zintchenko A: Hydrophobically Modified Oligoethylenimines as Highly Efficient Transfection Agents for siRNA Delivery. Bioconjugate Chem.; 2009, 20:2055-2061. [40]. Bruno K: Using drug-excipient interactions for siRNA delivery. Adv. Drug Deliver. Rev.; 2011, 63:1210-1226. [41]. Wang J, Lu Z, Wientjes MG, Au JLS: Delivery of siRNA Therapeutics: Barriers and Carriers. Aaps Journa;l 2010, 12:492-503. [42]. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK: RNA interference in the clinic: challenges and future directions. Nature Reviews Cancer; 2011, 11:59-67. [43]. Bora RS, Gupta D, Mukkur TKS, Saini KS: RNA interference therapeutics for cancer: Challenges and opportunities (Review). Molecular Medicine Reports; 2012, 6:9-15. [44]. Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J: Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. J. Control Release; 2015, 203:1-15. [45]. Nimesh S, Gupta N, Chandra R: Strategies and advances in nanomedicine for targeted siRNA delivery. Nanomedicine; 2011, 6:729-746. [46]. Krebs MD, Alsberg E: Localized, Targeted, and Sustained siRNA Delivery. Chem-Eur. J.; 2011, 17:3054-3062. [47]. Vicentini F, Borgheti-Cardoso LN, Depieri LV, Mano DD, Abelha TF, Petrilli R, Bentley M: Delivery Systems and Local Administration Routes for Therapeutic siRNA. Pharmaceut. Res.; 2013, 30:915-931. [48]. Larson SD, Jackson LN, Chen LA, Rychahou PG, Evers BM: Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery; 2007, 142:262-269. [49]. Kim HJ, Kim A, Miyata K, Kataoka K: Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv. Drug Deliver. Rev.; 2016, 104:61-77. [50]. Xiong XB, Uludag H, Lavasanifar A: Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials; 2009, 30:242-253. [51]. Snove O, Holen T: Many commonly used siRNAs risk off-target activity. Biochem. Bioph. Res. Co.; 2004, 319:256-263. [52]. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJC, Yamasaki S, Itaya M, Pan YZ, et al: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature; 2008, 452:591-U591. [53]. Forsbach A, Nemorin JG, Montino C, Muller C, Samulowitz U, Vicari AP, Jurk M, Mutwiri GK, Krieg AM, Lipford GB, Vollmer J: Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol.; 2008, 180:3729-3738. [54]. Forsbach A, Muller C, Montino C, Kritzler A, Curdt R, Benahmed A, Jurk M, Vollmer J: Impact of delivery systems on siRNA immune activation and RNA interference. Immunol. Lett.; 2012, 141:169-180. [55]. Williford JM, Wu J, Ren Y, Archang MM, Leong KW, Mao HQ: Recent Advances in Nanoparticle-Mediated siRNA Delivery. Annu. Rev. Biomed. Eng.;, Vol 16 2014, 16:347-370. [56]. Young SWS, Stenzel M, Yang JL: Nanoparticle-siRNA: A potential cancer therapy? Crit. Rev. Oncol. Hemat.; 2016, 98:159-169. [57]. Iyer AK, Khaled G, Fang J, Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today; 2006, 11:812-818. [58]. Greish K: Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J. Drug Target.; 2007, 15:457-464. [59]. Lin TY, Rodriguez CO, Li YP: Nanomedicine in veterinary oncology. Vet. J.; 2015, 205:189-197. [60]. Putnam D: Polymers for gene delivery across length scales. Nature Materials; 2006, 5:439-451. [61]. Brummelkamp TR, Bernards R, Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell; 2002, 2:243-247. [62]. Xia HB, Mao QW, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol.; 2002, 20:1006-1010. [63]. Tomar RS, Matta H, Chaudhary PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene; 2003, 22:5712-5715. [64]. Lee SJ, Yhee JY, Kim SH, Kwon IC, Kim K: Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice. J. Control Release; 2013, 172:358-366. [65]. Son S, Song S, Lee SJ, Min S, Kim SA, Yhee JY, Huh MS, Kwon IC, Jeong SY, Byun Y, et al: Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors. Biomaterials; 2013, 34:9475-9485. [66]. Wang Y, Li ZG, Han Y, Liang LH, Ji AM: Nanoparticle-Based Delivery System for Application of siRNA In Vivo. Current Drug Metabolism; 2010, 11:182-196. [67]. Rudzinski WE, Aminabhavi TM: Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm.; 2010, 399:1-11. [68]. Ragelle H, Vandermeulen G, Preat V: Chitosan-based siRNA delivery systems. J. Control Release; 2013, 172:207-218. [69]. Mao SR, Sun W, Kissel T: Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliver. Rev.; 2010, 62:12-27. [70]. Nicoli E, Syga MI, Bosetti M, Shastri VP: Enhanced Gene Silencing through Human Serum Albumin-Mediated Delivery of Polyethylenimine-siRNA Polyplexes. Plos One; 2015, 10. [71]. Malhotra A, Mittal BR: SiRNA gene therapy using albumin as a carrier. Pharmacogenetics and Genomics; 2014, 24:582-587. [72]. Kummitha CM, Malamas AS, Lu ZR: Albumin pre-coating enhances intracellular siRNA delivery of multifunctional amphiphile/siRNA nanoparticles. International Journal of Nanomedicine; 2012, 7:5205-5214. [73]. Ishikawa H, Nakamura Y, Jo J, Tabata Y: Gelatin nanospheres incorporating siRNA for controlled intracellular release. Biomaterials; 2012, 33:9097-9104. [74]. Loftsson T, Brewster ME: Pharmaceutical applications of cyclodextrins: basic science and product development. J. Pharm. Pharmacol.; 2010, 62:1607-1621. [75]. Chaturvedi K, Ganguly K, Kulkarni AR, Kulkarni VH, Nadagouda MN, Rudzinski WE, Aminabhavi TM: Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opinion on Drug Delivery; 2011, 8:1455-1468. [76]. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature; 2010, 464:1067-U1140. [77]. Helmschrodt C, Bauer A, Hobel S, Schoniger S, Fietz SA, Aigner A, Richter A, Richter F: Polyethylenimine (PEI) nanoparticle-mediated delivery of siRNA to silence neuronal gene expression of alpha-synuclein in a mouse model of Parkinson's disease. Movement Disord.; 2016, 31:S231-S231. [78]. Terrazas M, Kool ET: RNA major groove modifications improve siRNA stability and biological activity. Nucleic Acids Res.;2009, 37:346-353. [79]. Boussif O, Lezoualch F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP: A Versatile Vector For Gene And Oligonucleotide Transfer Into Cells In Culture And In-Vivo - Polyethylenimine. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7297-7301. [80]. Sonawane ND, Szoka FC, Verkman AS: Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem.; 2003, 278:44826-44831. [81]. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang QQ, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res.; 2004, 32. [82]. Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Demeneix BA: A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: Polyethylenimine. Hum. Gene Ther. 1996, 7:1947-1954. [83]. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther.; 2005, 12:461-466. [84]. Akhtar S, Benter I: Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliver Rev.; 2007, 59:164-182. [85]. Shim MS, Kwon YJ: Acid-Responsive Linear Polyethylenimine for Efficient, Specific, and Biocompatible siRNA Delivery. Bioconjugate Chem.; 2009, 20:488-499. [86]. Fischer D, Li YX, Ahlemeyer B, Krieglstein J, Kissel T: In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials; 2003, 24:1121-1131. [87]. Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, Benter IF, Akhtar S: Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J. Drug Target.; 2004, 12:393-404. [88]. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM: Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: Effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine-Nanotechnology Biology and Medicine 2007, 3:173-183. [89]. Patil Y, Panyam J: Polymeric nanoparticles for siRNA delivery and gene silencing. Int. J. Pharm.; 2009, 367:195-203. [90]. Katas H, Cevher E, Alpara HO: Preparation of polyethyleneimine incorporated poly(D,L-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Int. J. Pharm.; 2009, 369:144-154. [91]. Svenson S: Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm.; 2009, 71:445-462. [92]. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Konishi J, Togashi K, Brechbiel MW: Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magnet. Reson. Med.; 2001, 46:781-788. [93]. Yang H, Morris JJ, Lopina ST: Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J. Colloid Interf.Sci.; 2004, 273:148-154. [94]. Verdine GL, Walensky LD: The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members. Clin. Cancer Res.; 2007, 13:7264-7270. [95]. Patil A, Shaikh IM, Kadam VJ, Jadhav KR: Nanotechnology in Therapeutics - Current Technologies and Applications. Current Nanoscience; 2009, 5:141-153. [96]. Perrimon N, Ni JQ, Perkins L: In vivo RNAi: Today and Tomorrow. Cold Spring Harbor Perspectives in Biology 2010, 2. [97]. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, Brahmbhatt VN, Phillips L, Pattison ST, Petti C, et al: Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol.; 2009, 27:643-U697. [98]. Abbasi M, Lavasanifar A, Uludag H: Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med. Res. Rev.; 2013, 33:33-53. [99]. Saraswathy M, Gong SQ: Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Materials Today; 2014, 17:298-306. [100]. Parhi P, Mohanty C, Sahoo SK: Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov. Today; 2012, 17:1044-1052. [101]. Guo W, Chen WB, Yu WD, Huang WL, Deng WG: Small interfering RNA-based molecular therapy of cancers. Chinese Journal of Cancer 2013, 32:488-493. [102]. Lares MR, Rossi JJ, Ouellet DL: RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol.; 2010, 28:570-579. [103]. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol.; 2003, 21:639-644. [104]. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, Riazuddin S, Hassan S: RNAi as a new therapeutic strategy against HCV. Biotechnol. Adv.; 2010, 28:27-34. [105]. Li MJ, Li HT, Rossi JJ: RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Oligonucleotide Therapeutics; 2006, 1082:172-179. [106]. Kumar P, Ban HS, Kim SS, Wu HQ, Pearson T, Greiner DL, Laouar A, Yao JH, Haridas V, Habiro K, et al: T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586. [107]. Rondinone CM: Therapeutic potential of RNAi in metabolic diseases. Biotechniques; 2006, 40:31-36. [108]. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res.: 2004, 32:1154-1158. [109]. Czech MP, Aouadi M, Tesz GJ: RNAi-based therapeutic strategies for metabolic disease. Nat. Rev. Endocrinol,; 2011, 7:473-484. [110]. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, et al: Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12982-12987. [111]. Lee SH, Kang YY, Jang HE, Mok H: Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics. Adv. Drug Deliv. Rev.; 2016, 104:78-92.